MIRCERA 200mcg / ml injectible solution medication leaflet

B03XA03 methoxy-polyethylene glycol epoetin beta • Blood and blood forming organs | Other antianemic preparations

Methoxy polyethylene glycol-epoetin beta is an agent used for the treatment of anemia associated with chronic kidney disease or chemotherapy. This medication stimulates the production of red blood cells, helping to increase hemoglobin levels and reduce the need for blood transfusions.

It is a long-acting erythropoietic agent administered as a subcutaneous or intravenous injection. Due to its prolonged action, it can be administered less frequently than other similar medications.

The treatment must be closely monitored to avoid excessive increases in hemoglobin levels, which can raise the risk of thrombotic events. The dose is adjusted based on the patient's response and hemoglobin levels.

Side effects may include high blood pressure, headaches, or injection site reactions. Patients with hypersensitivity to this medication or a history of thrombosis should use this treatment with caution.

General data about MIRCERA 200mcg / ml

Substance: methoxy-polyethylene glycol epoetin beta

Date of last drug list: 01-07-2013

Commercial code: W52303001

Concentration: 200mcg / ml

Pharmaceutical form: injectible solution

Quantity: 1

Product type: original

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Pharmaceutical forms available for methoxy-polyethylene glycol epoetin beta

Concentrations available for methoxy-polyethylene glycol epoetin beta

1000mcg/ml, 100mcg/0.3ml, 100mcg/ml, 120mcg/0.3ml, 150mcg/0.3ml, 200mcg/0.3ml, 200mcg/ml, 250mcg/0.3ml, 300mcg/ml, 30mcg/0.3ml, 360mcg/0.6ml, 400mcg/0.6ml, 400mcg/ml, 40mcg/0.3ml, 50mcg/0.3ml, 50mcg/ml, 600mcg/0.6ml, 600mcg/ml, 60mcg/0.3ml, 75mcg/0.3ml, 800mcg/0.6ml